Article
CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumors
2025-10-01
Abstract excerpt
Chimeric antigen receptor T (CAR T) cells represent a promising therapeutic option for a variety of cancers, including solid tumors. Nectin-4 is a cell adhesion molecule expressed at different levels in many solid tumors, including breast and urothelial carcinoma (UC). Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) against Nectin-4, has significantly improved survival in patients with metastatic UC. Ski...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f6d89b94-dab0-5c85-a06b-e24c9257c805
- DOI
- 10.1101/2025.09.30.679440
